<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00844441</url>
  </required_header>
  <id_info>
    <org_study_id>2300.00</org_study_id>
    <secondary_id>P30CA015704</secondary_id>
    <secondary_id>FHCRC-2300.00</secondary_id>
    <secondary_id>IR 6845</secondary_id>
    <secondary_id>CDR0000631997</secondary_id>
    <nct_id>NCT00844441</nct_id>
  </id_info>
  <brief_title>Early Discharge and Outpatient Care After Chemotherapy in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia</brief_title>
  <official_title>Pilot Study of Feasibility, Safety, and Economics of Early Discharge and Outpatient Management of Adult Patients Following Intensive Induction Chemotherapy for Myelodysplastic Syndrome and Non-APL Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Gathering information about patients with myelodysplastic syndrome or acute&#xD;
      myeloid leukemia who are discharged after finishing chemotherapy, or who stay in the hospital&#xD;
      until blood counts return to normal, may help doctors learn more about a patient's quality of&#xD;
      life, use of medical services, and the cost of these services.&#xD;
&#xD;
      PURPOSE: This clinical trial is studying early discharge and outpatient care in patients who&#xD;
      have undergone chemotherapy for myelodysplastic syndrome or acute myeloid leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To compare the death rate in patients with myelodysplastic syndromes or acute myeloid&#xD;
           leukemia who are discharged after completion of induction chemotherapy vs those who&#xD;
           remain in the hospital until blood counts recover.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To determine the proportion of patients who meet the early discharge criteria after&#xD;
           completion of induction chemotherapy.&#xD;
&#xD;
        -  To compare the costs incurred by patients who are discharged early vs those who are&#xD;
           discharged only after blood counts recover.&#xD;
&#xD;
        -  To compare resource utilization (e.g., transfusions) among these patients.&#xD;
&#xD;
        -  To compare the quality of life of these patients.&#xD;
&#xD;
      OUTLINE: Within 72 hours after completion of induction chemotherapy, patients are either&#xD;
      discharged from the hospital or remain in the hospital until their blood counts recover.&#xD;
&#xD;
      Patients receive standard supportive care after completion of induction chemotherapy either&#xD;
      in the hospital or as an outpatient. Outpatients are seen by a registered nurse or physician&#xD;
      assistant ≥ 3 times weekly and by a physician at least once weekly.&#xD;
&#xD;
      A medical chart review is conducted to obtain information about medical complications (e.g.,&#xD;
      neutropenic fever, documented infections, bleeding, reasons for hospitalization) and use of&#xD;
      medical resources. Patients complete the MDA Symptom Inventory and the EORTC QLQ-C30&#xD;
      questionnaire periodically to assess quality of life. Costs associated with inpatient and&#xD;
      outpatient care are evaluated using electronic billing information from the University of&#xD;
      Washington Medical Center and Seattle Cancer Care Alliance.&#xD;
&#xD;
      After completion of the study, patients are followed up for 1 month.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Health Services Research</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Death rate in patients discharged after completion of induction chemotherapy</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of successful discharge of patients who meet medical discharge criteria</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Costs associated with outpatient vs inpatient treatment</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Medical resources used with outpatient vs inpatient treatment</measure>
  </primary_outcome>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>medical chart review</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>questionnaire administration</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of one of the following:&#xD;
&#xD;
               -  Myelodysplastic syndromes&#xD;
&#xD;
               -  Acute myeloid leukemia (AML)&#xD;
&#xD;
                    -  No acute promyelocytic leukemia with t(15;17)(q22;q12), PML/RAR, or other&#xD;
                       variants&#xD;
&#xD;
          -  Planning to undergo AML-like intensive induction chemotherapy (e.g., &quot;7+3&quot; or regimen&#xD;
             with similar or higher intensity) for untreated or relapsed disease within 1 week&#xD;
             after study entry OR has started therapy within the past 72 hours&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  No hypersensitivity or allergy to fluoroquinolones, triazoles, or acyclovir&#xD;
&#xD;
          -  ECOG/WHO/ZUBROD performance status 0-1*&#xD;
&#xD;
          -  Total bilirubin ≤ 2.5 times upper limit of normal (ULN) (unless elevation is thought&#xD;
             to be due to Gilbert's syndrome or hemolysis)*&#xD;
&#xD;
          -  AST and ALT ≤ 1.5 times ULN*&#xD;
&#xD;
          -  Serum creatinine ≤ 1.5 times ULN*&#xD;
&#xD;
          -  No clinical evidence of congestive heart failure*&#xD;
&#xD;
          -  No active bleeding*&#xD;
&#xD;
          -  Not refractory to platelet transfusions (e.g., due to HLA-alloimmunization)*&#xD;
&#xD;
          -  No requirement for IV antimicrobial therapy*&#xD;
&#xD;
          -  Agrees to undergo close follow-up that includes ≥ 3 visits per week at the Seattle&#xD;
             Cancer Care Alliance (SCCA)*&#xD;
&#xD;
          -  Has a confirmed reliable caregiver and transportation*&#xD;
&#xD;
          -  Confirmed temporary or permanent residency within a 30-minute commute from the&#xD;
             University of Washington (UW) Medical Center/SCCA*&#xD;
&#xD;
          -  Has identified a UW/SCCA hematologist/oncologist who is willing to care for the&#xD;
             patient in the outpatient clinic* NOTE: *Additional criteria for early discharge from&#xD;
             the hospital&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roland Walter, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97201-3098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Cancer Research Center at University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <zip>CH-4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <study_first_submitted>February 13, 2009</study_first_submitted>
  <study_first_submitted_qc>February 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 16, 2009</study_first_posted>
  <last_update_submitted>May 17, 2011</last_update_submitted>
  <last_update_submitted_qc>May 17, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2011</last_update_posted>
  <responsible_party>
    <name_title>Roland Walter</name_title>
    <organization>Fred Hutchinson Cancer Research Center</organization>
  </responsible_party>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>untreated adult acute myeloid leukemia</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute minimally differentiated myeloid leukemia (M0)</keyword>
  <keyword>adult acute myeloblastic leukemia without maturation (M1)</keyword>
  <keyword>adult acute myeloblastic leukemia with maturation (M2)</keyword>
  <keyword>adult acute myelomonocytic leukemia (M4)</keyword>
  <keyword>adult acute monoblastic leukemia (M5a)</keyword>
  <keyword>adult acute eosinophilic leukemia</keyword>
  <keyword>adult acute monocytic leukemia (M5b)</keyword>
  <keyword>adult acute megakaryoblastic leukemia (M7)</keyword>
  <keyword>adult acute basophilic leukemia</keyword>
  <keyword>acute myeloid leukemia with multilineage dysplasia following myelodysplastic syndrome</keyword>
  <keyword>adult erythroleukemia (M6a)</keyword>
  <keyword>adult pure erythroid leukemia (M6b)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

